The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
A Controlled Trial of Long-Term Inhaled Hypertonic Saline in Patients with Cystic Fibrosis
Open accessAbstract
BACKGROUND: Inhaled hypertonic saline acutely increases mucociliary clearance and, in short-term trials, improves lung function in people with cystic fibrosis. We tested the safety and efficacy of inhaled hypertonic saline in a long-term trial. METHODS: In this double-blind, parallel-group trial, 164 patients with stable cystic fibrosis who were at least six years old were randomly assigned to inhale 4 ml of either 7 percent hypertonic saline or 0.9 percent (control) saline twice daily for 48 weeks, with quinine sulfate (0.25 mg per milliliter) added to each solution to mask the taste. A bronchodilator was given before each dose, and other standard therapies were continued during the trial. RESULTS: The primary outcome measure, the rate of change (slope) in lung function (reflected by the forced vital capacity [FVC], forced expiratory volume in one second [FEV1], and forced expiratory flow at 25 to 75 percent of FVC [FEF25-75]) during the 48 weeks of treatment, did not differ significantly between groups (P=0.79). However, the absolute difference in lung function between groups was significant (P=0.03) when averaged across all post-randomization visits in the 48-week treatment period. As compared with the control group, the hypertonic-saline group had significantly higher FVC (by 82 ml; 95 percent confidence interval, 12 to 153) and FEV1 (by 68 ml; 95 percent confidence interval, 3 to 132) values, but similar FEF25-75 values. The hypertonic-saline group also had significantly fewer pulmonary exacerbations (relative reduction, 56 percent; P=0.02) and a significantly higher percentage of patients without exacerbations (76 percent, as compared with 62 percent in the control group; P=0.03). Hypertonic saline was not associated with worsening bacterial infection or inflammation. CONCLUSIONS: Hypertonic saline preceded by a bronchodilator is an inexpensive, safe, and effective additional therapy for patients with cystic fibrosis. (ClinicalTrials.gov number, NCT00271310.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1992) · PubMed · Cited by 33,716
The MOS 36-ltem Short-Form Health Survey (SF-36): I. Conceptual Framework and Item Selection
Ware, J. E., & Sherbourne, C. D. (1992) · Medical Care · doi:10.1097/00005650-199206000-00002 · Cited by 30,033
Littell, R. C. (1996) · Medical Entomology and Zoology · Cited by 10,547
Clinical Trials: A Practical Approach.
Hill, I. D., & Pocock, S. J. (1984) · Biometrics · doi:10.2307/2531186 · Cited by 2,930
Fuchs, H. J., Borowitz, D. S., Christiansen, D. H., Morris, E. M., Nash, M. L., Ramsey, B. W., Rosenstein, B. J., Smith, A. L., & Wohl, M. E. (1994) · New England Journal of Medicine · doi:10.1056/nejm199409083311003 · Cited by 1,539
Intermittent Administration of Inhaled Tobramycin in Patients with Cystic Fibrosis
Ramsey, B. W., Pepe, M. S., Quan, J. M., Otto, K. L., Montgomery, A. B., Williams-Warren, J., Vasiljev-K, M., Borowitz, D., Bowman, C. M., Marshall, B. C., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901073400104 · Cited by 1,300
Matsui, H., Grubb, B. R., Tarran, R., Randell, S. H., Gatzy, J. T., Davis, C. W., & Boucher, R. C. (1998) · Cell · doi:10.1016/s0092-8674(00)81724-9 · Cited by 1,169
Human β-Defensin-1 Is a Salt-Sensitive Antibiotic in Lung That Is Inactivated in Cystic Fibrosis
Goldman, M. J., Anderson, G. M., Stolzenberg, E. D., Kari, U. P., Zasloff, M., & Wilson, J. M. (1997) · Cell · doi:10.1016/s0092-8674(00)81895-4 · Cited by 1,080
Cystic Fibrosis Airway Epithelia Fail to Kill Bacteria Because of Abnormal Airway Surface Fluid
Smith, J. J., Travis, S. M., Greenberg, E. P., & Welsh, M. J. (1996) · Cell · doi:10.1016/s0092-8674(00)81099-5 · Cited by 1,039
Structure and Function of the CFTR Chloride Channel
SHEPPARD, D. N., & WELSH, M. J. (1999) · Physiological Reviews · doi:10.1152/physrev.1999.79.1.s23 · Cited by 1,018
Saiman, L., Marshall, B. C., Mayer-Hamblett, N., Burns, J. L., Quittner, A. L., Cibene, D. A., Coquillette, S., Fieberg, A. Y., Accurso, F. J., Campbell III, P. W., et al. (2003) · JAMA · doi:10.1001/jama.290.13.1749 · Cited by 958
Pulmonary Function Testing in Children. Techniques and Standards
(1973) · Clinical Pediatrics · doi:10.1177/000992287301200517 · Cited by 761
Predictive 5-year survivorship model of cystic fibrosis
Liou, T. G., Adler, F. R., FitzSimmons, S. C., Cahill, B. C., Hibbs, J. R., & Marshall, B. C. (2001) · American Journal of Epidemiology · doi:10.1093/aje/153.4.345 · Cited by 749
Mucus Clearance and Lung Function in Cystic Fibrosis with Hypertonic Saline
Donaldson, S. H., Bennett, W. D., Zeman, K. L., Knowles, M. R., Tarran, R., & Boucher, R. C. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa043891 · Cited by 694
New concepts of the pathogenesis of cystic fibrosis lung disease
Boucher, R. C. (2004) · European Respiratory Journal · doi:10.1183/09031936.03.00057003 · Cited by 640
Robinson, M., Hemming, A. L., Regnis, J. A., Wong, A. G., Bailey, D. L., Bautovich, G. J., King, M., & Bye, P. T. (1997) · Thorax · doi:10.1136/thx.52.10.900 · Cited by 265
Self-citationTarran, R., Grubb, B. R., Parsons, D., Picher, M., Hirsh, A. J., Davis, C. W., & Boucher, R. C. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00286-6 · Cited by 259
Robinson, M., Regnis, J. A., Bailey, D. L., King, M., Bautovich, G. J., & Bye, P. T. (1996) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.153.5.8630593 · Cited by 232
Self-citationSpirometry in the evaluation of pulmonary function.
Morris, J. F. (1976) · PubMed · Cited by 220
Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis
Eng, P. A., Morton, J., Douglass, J. A., Riedler, J., Wilson, J., & Robertson, C. F. (1996) · Pediatric Pulmonology · doi:10.1002/(sici)1099-0496(199602)21:2<77::aid-ppul3>3.0.co;2-m · Cited by 194
Quittner, A. L., Sweeny, S., Watrous, M., Munzenberger, P., Bearss, K., Nitza, A. G., Fisher, L. A., & Henry, B. (2000) · Journal of Pediatric Psychology · doi:10.1093/jpepsy/25.6.403 · Cited by 161
KING, M., DASGUPTA, B., TOMKIEWICZ, R. P., & BROWN, N. E. (1997) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.156.1.9512074 · Cited by 158
Wills, P. J., Hall, R. L., Chan, W., & Cole, P. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119138 · Cited by 129
Mechanisms and markers of airway inflammation in cystic fibrosis: Fig. 1.—
Rose, V. D. (2002) · European Respiratory Journal · doi:10.1183/09031936.02.00229202 · Cited by 114
Lung Inflammation as a Therapeutic Target in Cystic Fibrosis
Koehler, D. R., Downey, G. P., Sweezey, N., Tanswell, A. K., & Hu, J. (2004) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2004-0124tr · Cited by 111
Selective media for the quantitation of bacteria in cystic fibrosis sputum
WONG, K., ROBERTS, M. C., OWENS, L., FIFE, M., & Smith, A. L. (1984) · Journal of Medical Microbiology · doi:10.1099/00222615-17-2-113 · Cited by 93
Ballmann, M., & von der Hardt, H. (2002) · Journal of Cystic Fibrosis · doi:10.1016/s1569-1993(01)00009-1 · Cited by 72
Suri, R. (2002) · Thorax · doi:10.1136/thorax.57.10.841 · Cited by 57
Cytokines and Inflammatory Mediators Do Not Indicate Acute Infection in Cystic Fibrosis
Wolter, J. M., Rodwell, R. L., Bowler, S., & McCormack, J. G. (1999) · Clinical and Diagnostic Laboratory Immunology · doi:10.1128/cdli.6.2.260-265.1999 · Cited by 47
Cited by
A CFTR Potentiator in Patients with Cystic Fibrosis and the G551D Mutation
Ramsey, B. W., Davies, J., McElvaney, N. G., Tullis, E., Bell, S. C., Dřevínek, P., Griese, M., McKone, E. F., Wainwright, C. E., Konstan, M. W., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105185 · Cited by 2,195
Airway Mucus Function and Dysfunction
Fahy, J. V., & Dickey, B. F. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0910061 · Cited by 1,722
Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR
Wainwright, C. E., Elborn, J. S., Ramsey, B. W., Marigowda, G., Huang, X., Cipolli, M., Colombo, C., Davies, J. C., De Boeck, K., Flume, P. A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1409547 · Cited by 1,622
Stenotrophomonas maltophilia: an Emerging Global Opportunistic Pathogen
Brooke, J. S. (2012) · Clinical Microbiology Reviews · doi:10.1128/cmr.00019-11 · Cited by 1,434
O'Sullivan, B. P., & Freedman, S. D. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60327-5 · Cited by 1,320
Metadata
- Authors
- Elkins, M. R., Robinson, M., Rose, B. R., Harbour, C., Moriarty, C. P., Marks, G. B., Belousova, E. G., Xuan, W., & Bye, P. T. P.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-01-19
- Volume
- 354
- Issue
- 3
- Pages
- 229-240
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2103043501
- Cited by
- 862
- References
- 29
- FWCI
- 52.59
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.